Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

... have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease. Degeneration of these neurons is responsible for the major motor impairments of ... the putamen. The cell bodies for these same neurons are located in a different area of the brain, ...

Oprah, Luke Skywalker and Maradona -- new study investigates how our brains respond to them

... fascinating questions in neuroscience: how do neurons in the brain manage to abstract and disregard ... spoken and written names to show that single neurons in the human hippocampus and surrounding areas ... that such degree of abstraction in the sense that neurons fired the same to different pictures or the name ...

Novel drug discovery tool could identify promising new therapies for Parkinson's disease

... had a protective effect on the yeast cells and on neurons in an animal model of Parkinson's disease. ... for motor control and coordination. As those neurons degenerate, the disease leads to progressive ... stiffened muscles, and impaired balance. The neurons normally produce a chemical called dopamine. A ...

Scientists restore movement to paralyzed limbs through artificial brain-muscle connections

... interfaces to record signals from multiple neurons and convert those signals to control a robotic ... were designed to decode the activity of neurons known to be associated with movement of specific ... finding greatly expands the potential number of neurons that could control signals for brain-computer ...

Rutgers neuroscience may hold key to hearing loss remedy

... nerves to which they attach the spiral ganglion neurons that connect to the brain are the pianos ... have revealed that spiral ganglion auditory neurons possess a rich complexity that is only now ... proportions transforms the spiral ganglion neurons into either fast-firing transmitters to carry ...

JCI table of contents: Dec. 3, 2007

... cause cognitive impairment). Hypocretin/orexin neurons are brain cells that support wakefulness, but how ... Haven, have identified changes involving these neurons that occur in the brain of mice during prolonged sleep loss. Communication between neurons occurs across synapses, the junctions between ...

Scientists create colorful 'brainbow' images of the nervous system

... Lichtman. Brainbow allows researchers to tag neurons with roughly 90 distinct colors, a huge leap over ... of three or more fluorescent proteins in neurons can generate many different hues," says Lichtman, ... different colors to neurons. This variation makes neurons leap out from one another visually under ordinary ...

Treatment blocks pain without disrupting other functions

... of two drugs can selectively block pain-sensing neurons in rats without impairing movement or other ... tested the combination of capsaicin and QX-314 in neurons isolated in Petri dishes and found that it blocked pain-sensing neurons without affecting other nerve cells. They then ...

Microfluidic chambers advance the science of growing neurons

... have developed a method for culturing mammalian neurons in chambers not much larger than the neurons themselves. The new approach extends the lifespan of the neurons at very low densities, an essential step toward ...

Stem cells' 'suspended' state preserved by key step, scientists report

... for example, would allow scientists to study the mechanisms that cause neurons in the brain to develop the disease. It also could lead to treatments by directing the restored stem cells to produce healthy neurons to introduce into patients. The new research, conducted on mouse embryo ...

'Adipose-derived' Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Group's, Entest BioMedical Inc. Researcher

... brain ischemia and inflammation and replacement of damaged neurons with neuron cells differentiated from fat cells." Bio-Matrix Scientific ... initial brain damage caused by trauma," stated Dr. Lin. "Brain cells or neurons have limited ability for self-repair and spontaneous axonal regeneration. ...

New stem cell tools to aid drug development

... For example, EC23 was found to be particularly effective at producing neurons (nerve cells) which can be used in laboratory testing for drugs for brain ... development work. EC23, for example, produces almost 40 per cent more neurons than ATRA." Dr Whiting said: "We've set out to make stable mimics of ...

Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more

... traditionally been done by lining up tiny electrodes within or near single neurons to probe their electrical activity. Though well established, this method ... are used to optically sense the local electric fields produced when nearby neurons fire. The neuronal activity modulates the electron density at the surface ...

Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy

... 2005 showing that transplants of mouse embryonic stem cell-derived motor neurons into the spinal cord can connect with muscles and partially restore ... through the use of stem cells is the only means to replace motor neurons once they are gone. This strategy may be useful for treating multiple ...

Vasogen's Research Published in European Journal of Neuroscience

... which produce the neurotransmitter dopamine. It is the loss of these neurons and thereby the dopamine they produce that results in the movement ... to three weeks while partial protection against the loss of dopaminergic neurons and reduction in striatal dopamine levels was still evident four weeks ...

Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference

... 2010, and Empatic(TM) which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can ...

Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board

... and pathophysiological conditions. Following a similar paradigm, Professor Julius' research showed that a menthol receptor from primary sensory neurons is activated by cold thermal stimuli, and that the structure of this menthol/cold receptor, TRPM8, resembles that of TRPV1. Professor Julius ...

Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters

... of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. ...

Practice makes perfect -- motor memory possible for neuroprosthetic control

... and quickly for the next two weeks. As the tasks were being completed, the researchers were able to monitor the changes in activity of individual neurons involved in controlling the cursor. They could tell which cells were active when the cursor moved in specific directions. The researchers noticed ...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can ...

New MIT radio chip mimics human ear

... working on projects inspired by signal processing in cells. In the past, his group has worked on hybrid analog-digital signal processors inspired by neurons in the brain. Sarpeshkar says that engineers can learn a great deal from studying biological systems that have evolved over hundreds of millions ...

Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can ...

New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers

... the forefront of mitochondrial physiology his entire career. Most recently he has focused on studying bioenergetics in intact cells, specifically in neurons in order to understand life and death decisions that are pathologic in neurodegenerative diseases. His lab's focus on putting bioenergetics in the ...

DFG establishes 14 new research training groups

... electrons in nonequilibrium through semiconductor quantum dots, to nanorods that swim in aqueous solutions and that are driven by shear flow, to neurons in the brain. With the description of the collective dynamics of interacting units in nonequilibrium, the Research Training Group is concentrating on ...

Orexigen(R) Therapeutics to Present at Upcoming Meetings

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be ...

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be ...

Orexigen(R) Therapeutics to Speak at Upcoming Conferences

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can ...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

... as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be ...

Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be ...

Accera, Inc. Launches Neuera Pharmaceuticals, Inc.

... symptoms or diagnosis of AD and worsens as the disease progresses. Axona was developed as a substitute for glucose when it cannot be metabolized by neurons in the brain. About Accera, Inc. Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets ...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.

... was the first to accomplish both commercial quantities and controlled differentiation of neural stem cells into mature, physiologically relevant neurons and glia. The initial product candidate of this therapeutic platform is a spinal cord cell line. When implanted into animal models, the cells ...

Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008

... as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be ...

Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease

... said Steve Orndorff, Ph.D., founder and CEO, Accera, Inc. "Similar to how insulin helps diabetics, Axona supplements energy for the brain so that neurons can continue to function properly and patients can maintain cognition. As a company focused on developing new therapies for central nervous system ...

Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference

... trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be ...

deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor

... and the United States. It is located on the long arm of chromosome 15 in the LINGO1 gene, which encodes a protein that has been shown to affect how neurons are formed and signal each other. This makes the finding even more significant, for although essential tremor is a relatively common neurological ...

Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference

... and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic ...

Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent

... and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic ...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can ...

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

... and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be ...

New label-free method tracks molecules and drugs in live cells

... and treat the growing imbalance of saturated and unsaturated fats in our diets." SRS microscopy could also prove useful in neuroimaging, since neurons are coated with fatty myelin sheaths. The researchers' use of SRS microscopy to analyze skin tissue could also open new frontiers in drug ...